CLDN18.2-话题@MedSci

#CLDN18.2#

1篇内容 | 1297人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2276675, encodeId=b6ad22e66750c, content=<a href='/topic/show?id=50a510662947' target=_blank style='color:#2F92EE;'>#CLDN18.2#</a> <a href='/topic/show?id=cde9129222b6' target=_blank style='color:#2F92EE;'>#胃癌及胃食管结合部腺癌#</a>, objectTitle=沈琳教授团队重大突破！靶向CLDN18.2的ADC药物IBI343展现强劲潜力，有望革新晚期胃癌及胃食管结合部腺癌治疗模式！, objectType=article, longId=891011, objectId=9576891011a9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/health-insurance-PK235DP.jpg, objectUrl=/article/show_article.do?id=9576891011a9, replyNumber=0, likeNumber=15, createdTime=2025-08-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=9576891011a9, moduleTitle=沈琳教授团队重大突破！靶向CLDN18.2的ADC药物IBI343展现强劲潜力，有望革新晚期胃癌及胃食管结合部腺癌治疗模式！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9576891011a9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2208739, encodeId=f1482208e391d, content=<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> <a href='/topic/show?id=0d3240e64e' target=_blank style='color:#2F92EE;'>#CAR-T细胞治疗#</a> <a href='/topic/show?id=50a510662947' target=_blank style='color:#2F92EE;'>#CLDN18.2#</a>, objectTitle=Nat med：科济药业CAR-T疗法CT041治疗CLDN18.2阳性胃癌疗效显著！96.1%疾病控制率！, objectType=article, longId=829076, objectId=dc428290e663, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240529/f7b2056d9d644c84a9056c99d711fcaa-YPQIVAdq7NcK.jpg, objectUrl=/article/show_article.do?id=dc428290e663, replyNumber=0, likeNumber=153, createdTime=2024-06-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=dc428290e663, moduleTitle=Nat med：科济药业CAR-T疗法CT041治疗CLDN18.2阳性胃癌疗效显著！96.1%疾病控制率！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc428290e663)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2176143, encodeId=81d021e61433c, content=<a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a> <a href='/topic/show?id=213b8334e10' target=_blank style='color:#2F92EE;'>#胃肠道癌症#</a> <a href='/topic/show?id=50a510662947' target=_blank style='color:#2F92EE;'>#CLDN18.2#</a>, objectTitle=读书报告 | 靶向CLDN18.2治疗消化道肿瘤, objectType=article, longId=806132, objectId=3bd6806132a6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, objectUrl=/article/show_article.do?id=3bd6806132a6, replyNumber=0, likeNumber=174, createdTime=2023-12-20, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3bd6806132a6, moduleTitle=读书报告 | 靶向CLDN18.2治疗消化道肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bd6806132a6)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2158118, encodeId=a71f21581188b, content=GLOW研究：<a href='/topic/show?id=3c0c105e4850' target=_blank style='color:#2F92EE;'>#Zolbetuximab#</a>+CAPOX一线治疗<a href='/topic/show?id=50a510662947' target=_blank style='color:#2F92EE;'>#CLDN18.2#</a>+/HER2-局晚期或转移性胃或食管胃结合部腺癌 <a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> , objectTitle=ASCO月会 | GLOW研究结果出炉：Zolbetuximab+CAPOX一线治疗CLDN18.2+/HER2-胃癌疗效显著！, objectType=article, longId=791993, objectId=c08ce9199328, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/black-surgeon-giving-instruction-to-medical-team-TMPFGNZ.jpg, objectUrl=/article/show_article.do?id=c08ce9199328, replyNumber=0, likeNumber=143, createdTime=2023-09-17, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=广东省, moduleDTOList=[ModuleDTO(moduleId=c08ce9199328, moduleTitle=ASCO月会 | GLOW研究结果出炉：Zolbetuximab+CAPOX一线治疗CLDN18.2+/HER2-胃癌疗效显著！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c08ce9199328)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 侠胆医心

GLOW研究：Zolbetuximab+CAPOX一线治疗CLDN18.2+/HER2-局晚期或转移性胃或食管胃结合部腺癌胃癌

2023-09-17发表于广东省

梅斯管理员 (审核中...)

前往app查看评论内容

#CLDN18.2# #胃癌及胃食管结合部腺癌#

沈琳教授团队重大突破！靶向CLDN18.2的ADC药物IBI343展现强劲潜力，有望革新晚期胃癌及胃食管结合部腺癌治疗模式！

2025-08-10发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#胃癌# #CAR-T细胞治疗# #CLDN18.2#

Nat med：科济药业CAR-T疗法CT041治疗CLDN18.2阳性胃癌疗效显著！96.1%疾病控制率！

2024-06-07发表于威斯康星

梅斯管理员 (审核中...)

前往app查看评论内容

#CAR-T# #胃肠道癌症# #CLDN18.2#

读书报告 | 靶向CLDN18.2治疗消化道肿瘤

2023-12-20发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

GLOW研究：#Zolbetuximab#+CAPOX一线治疗#CLDN18.2#+/HER2-局晚期或转移性胃或食管胃结合部腺癌 #胃癌#

ASCO月会 | GLOW研究结果出炉：Zolbetuximab+CAPOX一线治疗CLDN18.2+/HER2-胃癌疗效显著！

2023-09-17发表于广东省

科室
- - 订阅+
  - 更多科室
工具
服务